130 related articles for article (PubMed ID: 36094308)
1. Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.
Longshaw C; Roger E; Santerre Henriksen A; Baba T; Nguyen S; Yamano Y
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0110022. PubMed ID: 36094308
[No Abstract] [Full Text] [Related]
2. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Nordmann P; Shields RK; Doi Y; Takemura M; Echols R; Matsunaga Y; Yamano Y
Microb Drug Resist; 2022 Apr; 28(4):398-407. PubMed ID: 35076335
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Timsit JF; Paul M; Shields RK; Echols R; Baba T; Yamano Y; Portsmouth S
Clin Infect Dis; 2022 Sep; 75(6):1081-1084. PubMed ID: 35148378
[TBL] [Abstract][Full Text] [Related]
4. No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales.
Jacob AS; Chong GL; Lagrou K; Depypere M; Desmet S
J Antimicrob Chemother; 2021 Nov; 76(12):3317-3318. PubMed ID: 34427311
[No Abstract] [Full Text] [Related]
5. Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.
Simner PJ; Beisken S; Bergman Y; Ante M; Posch AE; Tamma PD
Microb Drug Resist; 2022 Feb; 28(2):161-170. PubMed ID: 34619049
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
7.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
Silva JT; López-Medrano F
Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
11. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Poirel L; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0087721. PubMed ID: 34252309
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
13. Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.
Paterson DL; Kinoshita M; Baba T; Echols R; Portsmouth S
Infect Dis Ther; 2022 Apr; 11(2):853-870. PubMed ID: 35184255
[TBL] [Abstract][Full Text] [Related]
14. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
[TBL] [Abstract][Full Text] [Related]
15. Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.
Longshaw CM; Santerre Henriksen A; Slover C; Yamano Y; Karas JA
J Antimicrob Chemother; 2022 Sep; 77(10):2895-2896. PubMed ID: 35971761
[No Abstract] [Full Text] [Related]
16. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
19. Evolution of β-lactamase-mediated cefiderocol resistance.
Fröhlich C; Sørum V; Tokuriki N; Johnsen PJ; Samuelsen Ø
J Antimicrob Chemother; 2022 Aug; 77(9):2429-2436. PubMed ID: 35815680
[TBL] [Abstract][Full Text] [Related]
20. First Occurrence of the OXA-198 Carbapenemase in
Bonnin RA; Jousset AB; Gauthier L; Emeraud C; Girlich D; Sauvadet A; Cotellon G; Jové T; Dortet L; Naas T
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
